Back to search

Article

Real-world Effectiveness of Casirivimab Plus Indevimab in a Dedicated Ambulatory Unit Created for Patients With Early COVID During a Massive Delta Variant Wave

2022-01-31

Abstract excerpt

<title>Abstract</title> <p>Only few data are available on real-life effectiveness of neutralizing monoclonal antibodies to avoid hospitalization in high-risk patients with early COVID-19 not requiring supplemental oxygen. Our study analyzed the efficacy of casirivimab plus indevimab to prevent unfavorable outcomes in these patients. A dedicated Hospital Day Unit was created to treat during our 4<sup>th</sup> COVI...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2b910c3f-c5ed-5688-977c-90fbbc3ca3b2
DOI
10.21203/rs.3.rs-1259083/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world Effectiveness of Casirivimab Plus Indevimab in a Dedicated Ambulatory Unit Created for Patients With Early COVID During a Massive Delta Variant WaveDOI 10.21203/rs.3.rs-1259083/v1
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesSemantic proximity
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trialSemantic proximity
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of ConcernSemantic proximity
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant InfectionSemantic proximity
Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron SurgeSemantic proximity
Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims DatabaseSemantic proximity
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity
Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBsSemantic proximity
Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trialsSemantic proximity
Select a neighboring publication to make it the new centre.